Tagged with Strategy,

Ukraine Eugene Zaika, general director Ukraine and CIS of Pharma Start, a company acquired in October 2015 by Swiss-headquartered Acino Group and one of the leading players in Ukraine, provides insights into the group’s countercyclical investments in Ukraine, while Pharma Start’s ongoing successes prove that the risk taken is actually paying…

Ukraine Vladimir Tkachenko, general manager of AMAXA PHARMA, a UK-headquartered pharmaceutical company focused on life-threatening therapeutic areas such as oncology and neonatology in the CIS countries, provides insights into AMAXA’s market positioning in Ukraine and the region, as well as his strategic priorities to further propel the eye-catching development pace of…

Indonesia Darodjatun Sanusi, Executive Director of GP Farmasi (National Association of Local Companies in Indonesia), explains the opportunities and challenges that his members are facing as well as the future directions that the industry should take to further enhance its capabilities and continue its growth. As Executive Director of GP Farmasi,…

Indonesia Rufi Susanto, President (Core Market) and Senior Managing Director IDS Medical Systems (idsMED), highlights the company’s commitment to Indonesia and believes that idsMED’s employees, in combination with continuous investment in their education, are key to making the company succeed. Mr. Susanto, you hold two management roles within idsMED, being the…

Hong Kong Lawrence Wong, general manager of Ferring Pharmaceuticals in Hong Kong, discusses the important role of the Hong Kong affiliate in support of regional operations, the value of the Hong Kong market given that Ferring offers most of its global portfolio here, and how the company philosophy ‘People come first at…

Indonesia Steven Lee, country lead at Siemens Healthineers Indonesia, expands on the strategic change that the company is undergoing in order to fully capture the potential of the Indonesian public and private market. In 2015, Siemens made its healthcare unit an independent organization and just a year ago changed its name…

Hong Kong William Yim and Kelvin Chiu of Sanwa Biotech discuss their innovative company’s impressive growth and the environment for biotech start-up companies in Hong Kong. Despite only having been founded five years ago in 2012, Sanwa BioTech has seen tremendous progress. Can you highlight some of the main development milestones? “Our…

Colombia Sunil Dhyani, general manager of IPCA in Colombia, a successful Indian firm continuously launching new molecules, shares his take on the company’s strategy decisions in Colombia, as well as wider opportunities in Latin America. How does Colombia differentiate itself from other markets in the region? “Colombia offers a great political…

Colombia Francois Léger, recently appointed GM of Servier Colombia discusses his strategy to achieve the company’s ambitious growth plans to launch eight new products within the next three years. You have been appointed General Manager four months ago. Can you introduce yourself to our executive readership? Being originally from France and…

Colombia Pfizer’s country manager and PEH Lead for Colombia & Venezuela, Diego Forero, shares his insights on the Colombian pharmaceutical market, his goals for Pfizer’s Colombian affiliate, and how Colombian operations fit into the group’s worldwide strategy. You just returned after eight years in the USA to lead Pfizer’s Colombian affiliate.…

Switzerland Paul Note, CEO of leading Swiss tissue and bone regeneration specialist Geistlich, discusses how the medtech industry can safeguard success against a challenging economic backdrop, the company’s total commitment to innovation, and its internationalization strategy. Could you please introduce Geistlich to our audience? “We are fortunate to bank upon a…

Colombia J&J Medical Devices regional VP Mircea Cubillos discusses the long-term vision for J&J in Colombia and Latin America. Moreover, he speaks about the company’s strategy for emerging markets, the importance of the collaboration with stakeholders and government actors in the medical devices sector, as well as his personal motivation to…